(NASDAQ: MRVI) Maravai Lifesciences Holdings's forecast annual revenue growth rate of 0.18% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 260.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.12%.
Maravai Lifesciences Holdings's revenue in 2025 is $215,853,000.On average, 3 Wall Street analysts forecast MRVI's revenue for 2025 to be $49,400,005,825, with the lowest MRVI revenue forecast at $47,715,639,042, and the highest MRVI revenue forecast at $51,455,413,380. On average, 3 Wall Street analysts forecast MRVI's revenue for 2026 to be $54,939,570,502, with the lowest MRVI revenue forecast at $52,349,179,865, and the highest MRVI revenue forecast at $57,030,473,354.
In 2027, MRVI is forecast to generate $62,017,690,343 in revenue, with the lowest revenue forecast at $62,017,690,343 and the highest revenue forecast at $62,017,690,343.